The Effect Of Alfuzosin And Tolterodine In Treating Double-J Stent-Related Symptoms

Main Category: Urology / Nephrology
Article Date: 15 Jun 2008 - 4:00 PDT

email to a friend   printer friendly   opinions  

ORLANDO, FL (UroToday.com) - In this Level I prospective randomized study, either alfuzosin (10 mg) or tolterodine (4mg) per day, resulted in a statistically significant equal decrease in ureteral stent symptoms. However, the overall decrease for either drug was only 21%.

Of interest, but understandable, the pain index decreased more with alfuzosin ( a 50% drop) while the symptoms of bladder irritation decreased more with tolterodine (but only by 8-21%). Unfortunately, there was no arm in which both drugs were used.

In sum, among patients undergoing stent placement, complaints of discomfort could likely be addressed with alfuzosin rather than analgesics; unfortunately, complaints of irritative voiding symptoms can not be effectively addressed pharmacologically - for these patients only stent removal is of benefit.

Presented by Seung Chol Park, MD, Jea Whan Lee, MD, Ill Young Se, MD, Hee Jong Jeong, MD, Sang Jin Oh, MD, Joung Sik Rim, MD, and Young Beom Jeong, MD at the Annual Meeting of the American Urological Association (AUA) - May 17 - 22, 2008. Orange County Convention Center - Orlando, Florida, USA.

Reported by UroToday.com Medical Editor Ralph V. Clayman, MD

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to: www.urotoday.com

Copyright © 2008 - UroToday

• Additional
• References
• Citations